Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients.

Anthony K C ChanJayanthi AlameluChris BarnesAmpaiwan ChuansumritMay-Lill GarlyRikke Medom MeldgaardGuy Aaron Young

Published in: Research and practice in thrombosis and haemostasis (2020)

We report an inhibitor incidence of 6.1%, which is within the expected range for PUPs with hemophilia B. No other safety concerns were identified; moreover, N9-GP provided effective hemostatic coverage.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
risk factors
peritoneal dialysis
prognostic factors
healthcare
patient reported outcomes
patient reported
health insurance